Abbott Laboratories — SEC Form 4 Filings
SEC Form 4 Data
Track insider buying and selling activity for Abbott Laboratories (ABT). Data sourced from SEC EDGAR Form 4 filings and analyzed by StoxPulse AI for significance.
15
$1.3M total
2
$78K total
7.5x
Bullish Signal
17
Form 4 transactions
Buy − Sell value
Buy · Apr 27, 2026
Morrone · Sale
Abbott Laboratories insiders filed 17 Form 4 transactions in the period analyzed: 15 purchases totaling $1.3M and 2 sales totaling $78K. That puts the buy-to-sell ratio at 7.50, which we read as bullish on a directional basis.
The most active filer was Stratton John G with 2 transactions in this window. 14 of the 17 filings are flagged as routine — typically 10b5-1 scheduled trades rather than discretionary signals.
Form 4 filings are point-in-time disclosures and do not constitute investment advice. Routine sales under pre-arranged 10b5-1 plans should not be read as bearish.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Sale | 269 | $92.71 | $25K | 2026-06-30 |
| Cushman Elizabeth C. | EVP, GC AND SECRETARY | Sale | 560 | $94.12 | $53K | 2026-06-27 |
| Stratton John G | Director | Buy | 2,000 | $86.82 | $174K | 2026-05-07 |
| STARKS DANIEL J | Director | Buy | 10,000 | $92.65 | $927K | 2026-04-27 |
| Conroy Kevin T | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Stratton John G | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| STARKS DANIEL J | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Roman Michael F | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| O'Grady Michael | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| McKinstry Nancy | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| McDew Darren W | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Kumbier Michelle | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Gonzalez Patricia Paola | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Blount Sally E. | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Babineaux-Fontenot Claire | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Ahuja Nita | Director | Buy | 2,286 | $0.00 | $0.00 | 2026-04-24 |
| Boudreau Philip P | EVP AND CFO | Buy | 2,200 | $91.50 | $201K | 2026-04-23 |
Insider trading data for Abbott Laboratories (ABT) is sourced directly from SEC Form 4 filings on the EDGAR database. Corporate insiders — including directors, officers, and shareholders owning more than 10% of the company — are legally required to report their transactions within two business days.
Insider purchases are often considered a bullish signal because executives are using their own money to buy shares, suggesting they believe the stock is undervalued. Insider sales, on the other hand, are more nuanced — they can reflect routine diversification plans (known as 10b5-1 plans), tax obligations, or genuine concerns about the company's outlook.
StoxPulse's AI system analyzes each ABT insider transaction to determine whether it appears routine or notable. We track the buy/sell ratio, total transaction values, and patterns over time to provide a clear picture of insider sentiment for Abbott Laboratories.
AI earnings, financials, news & more
Translate any filing into plain English
Disclaimer: Insider trading data for Abbott Laboratories (ABT) is sourced from SEC Form 4 filings and is provided for informational purposes only. Insider transactions should not be the sole basis for investment decisions. Always consult a qualified financial advisor.
Join the waitlist to receive instant AI notifications when Abbott Laboratories insiders buy or sell shares.
Join the Waitlist